Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
Prospector Capital Appreciation PCAFX
- NAV / 1-Day Return 22.79 / +0.97 %
- Total Assets 41.7 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.260%
- Distribution Fee Level High
- Share Class Type No Load
- Category Moderately Aggressive Allocation
- Investment Style Mid Blend
- Credit Quality / Interest Rate Sensitivity —
- Status Open
- TTM Yield 0.49%
- Turnover 41%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:17 PM GMT+0
Morningstar’s Analysis PCAFX
Will PCAFX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 27.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
First American Treasury Obligs X | 5.65 | 2.2 Mil | Cash and Equivalents |
Eaton Corp PLC | 4.07 | 1.6 Mil | Industrials |
Leidos Holdings Inc | 3.17 | 1.2 Mil | Technology |
Halozyme Therapeutics Inc 1% | 2.68 | 1.0 Mil | Corporate |
Fairfax Financial Holdings Ltd Shs Subord.Vtg | 2.62 | 1.0 Mil | Financial Services |
Merck & Co Inc | 2.62 | 1.0 Mil | Healthcare |
Curtiss-Wright Corp | 2.50 | 976,883 | Industrials |
Brown & Brown Inc | 2.50 | 975,463 | Financial Services |
Hess Corp | 2.43 | 948,111 | Energy |
Abbott Laboratories | 2.36 | 923,240 | Healthcare |